← Leaderboards
Rekha Bansal
Novelmed Therapeutics, Inc.
$18,235,492
Attributed
$19,580,107
Total exposure
21
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$19,580,107 · 21
By mechanism
R44$17,703,337 · 13
R43$1,876,770 · 8
Top collaborators
- Michael Zhao3 shared
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventProductionComplementMonoclonal AntibodiesPharmaceutical PreparationsSafetyDoseOryctolagus CuniculusComplement 3aComplement 5aBasePathway InteractionsBinding (Molecular Function)AntibodiesAlternative Complement PathwayInflammatoryInflammation MediatorsIn VitroLeadDrug KineticsInhibitor/AntagonistProperdinCytokineInflammation
Grant awards (40)
Disease Modifying Treatment for Hemolytic Disorders$533,165
R44 · FY2021 · HL · contact PI
Treatment of Complement-Mediated Myelitis$300,000
R44 · FY2021 · AG · contact PI
Preclinical and Clinical Evaluation of Humanized NM9405$1,277,607
R44 · FY2017 · HL · contact PI
Preclinical and Clinical Evaluation of Humanized NM9405$1,159,286
R44 · FY2015 · HL · contact PI
Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis$601,912
R44 · FY2015 · DK · contact PI
Single Therapy for Wet AMD & Geographic Atrophy$39,400
R44 · FY2015 · EY · contact PI
Alternative Pathway Inhibitors for Orphan Indication$889,438
R44 · FY2014 · HL · contact PI
Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis$849,661
R44 · FY2014 · DK · contact PI
Single Therapy for Wet AMD & Geographic Atrophy$548,724
R44 · FY2014 · EY · contact PI
Preclinical and Clinical Evaluation of Humanized NM9405$467,832
R44 · FY2014 · HL · contact PI
Complement Inhibitors for Macular Degeneration$239,000
R44 · FY2014 · EY · contact PI
Complement Inhibitors for Macular Degeneration$25,000
R44 · FY2014 · EY · contact PI
Complement Inhibitors for Macular Degeneration$597,897
R44 · FY2013 · EY · contact PI
Alternative Pathway Inhibitors for Orphan Indication$542,572
R44 · FY2013 · HL · contact PI
Complement Inhibitors as DMOADs$307,870
R44 · FY2013 · AG · contact PI
Complement Inhibitors as DMOADs$78,750
R44 · FY2013 · AG · contact PI
Disease Modifying Biologics for Rheumatoid Arthritis$968,470
R44 · FY2012 · AG · contact PI
Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs$691,377
R44 · FY2012 · HL · contact PI
Controlling Inflammation Due to Cardiac Devices$633,313
R44 · FY2012 · HL · contact PI
Complement Inhibitors for Macular Degeneration$466,354
R44 · FY2012 · EY · contact PI
Complement Inhibitors as DMOADs$294,766
R44 · FY2012 · AG · contact PI
Disease Modifying Biologics for Rheumatoid Arthritis$929,079
R44 · FY2011 · AG · contact PI
Controlling Inflammation Due to Cardiac Devices$719,654
R44 · FY2011 · HL · contact PI
Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs$503,352
R44 · FY2011 · HL · contact PI
Disease Modifying Biologics for Rheumatoid Arthritis$791,681
R44 · FY2010 · AG · contact PI
Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs$516,118
R44 · FY2010 · HL · contact PI
Controlling Inflammation Due to Cardiac Devices$420,195
R44 · FY2010 · HL · contact PI
Neutralizing Antibodies for Complement Inhibition$300,000
R43 · FY2010 · AI · contact PI
Device for Surgical Adhesion Prevention$266,001
R43 · FY2010 · GM · contact PI
Novel Anti-Inflammatories for Cardiopulmonary Bypass$522,061
R44 · FY2009 · HL · contact PI
Anti-Inflammatory Cardiovascular Device$273,190
R43 · FY2009 · HL · contact PI
Small Molecule TNF-alpha Inhibitor for the Treatment of Arthritis$249,927
R43 · FY2009 · AR · contact PI
Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis$233,538
R43 · FY2009 · DK · contact PI
Complement Inhibitors for Macular Degeneration$212,118
R43 · FY2009 · EY · contact PI
Complement Inhibitors for Macular Degeneration$31,982
R43 · FY2009 · EY · contact PI
Novel Anti-Inflammatories for Cardiopulmonary Bypass$963,269
R44 · FY2008 · HL · contact PI
Anti-Properdin MoAb as a novel therapeutics for arthritis$411,015
R44 · FY2007 · AR · contact PI
Anti-Properdin MoAb as a novel therapeutics for arthritis$414,519
R44 · FY2006 · AR · contact PI
Novel Anti-Inflammatories for Cardiopulmonary Bypass$206,911
R43 · FY2005 · HL
Anti-Properdin MoAb as a Novel Therapeutic for Arthritis$103,103
R43 · FY2003 · AR